Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 3.73
ALIOF's Cash to Debt is ranked higher than
64% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ALIOF: 3.73 )
ALIOF' s 10-Year Cash to Debt Range
Min: 3.31   Max: No Debt
Current: 3.73

Equity to Asset 0.56
ALIOF's Equity to Asset is ranked higher than
62% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALIOF: 0.56 )
ALIOF' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.66
Current: 0.56

0.5
0.66
F-Score: 7
Z-Score: 6.63
M-Score: -2.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Revenue Growth (%) -0.90
ALIOF's Revenue Growth (%) is ranked higher than
75% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. ALIOF: -0.90 )
ALIOF' s 10-Year Revenue Growth (%) Range
Min: -25.8   Max: 21.5
Current: -0.9

-25.8
21.5
EBITDA Growth (%) 2.50
ALIOF's EBITDA Growth (%) is ranked higher than
85% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. ALIOF: 2.50 )
ALIOF' s 10-Year EBITDA Growth (%) Range
Min: -48.4   Max: 37.7
Current: 2.5

-48.4
37.7
EPS Growth (%) 6.80
ALIOF's EPS Growth (%) is ranked higher than
82% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. ALIOF: 6.80 )
ALIOF' s 10-Year EPS Growth (%) Range
Min: -35.8   Max: 47.7
Current: 6.8

-35.8
47.7
» ALIOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ALIOF Guru Trades in

ALIOF Guru Trades in

Q2 2012

ALIOF Guru Trades in Q2 2012

Vanguard Health Care Fund 200,000 sh (New)
» More
Q3 2012

ALIOF Guru Trades in Q3 2012

Vanguard Health Care Fund 200,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ALIOF



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.00
ALIOF's P/E(ttm) is ranked higher than
67% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. ALIOF: 22.00 )
ALIOF' s 10-Year P/E(ttm) Range
Min: 13.52   Max: 66.51
Current: 22

13.52
66.51
P/B 5.60
ALIOF's P/B is ranked lower than
51% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ALIOF: 5.60 )
ALIOF' s 10-Year P/B Range
Min: 2.35   Max: 5.95
Current: 5.6

2.35
5.95
P/S 5.50
ALIOF's P/S is ranked higher than
72% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. ALIOF: 5.50 )
ALIOF' s 10-Year P/S Range
Min: 1.96   Max: 16.68
Current: 5.5

1.96
16.68
PFCF 17.70
ALIOF's PFCF is ranked higher than
80% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 31.10 vs. ALIOF: 17.70 )
ALIOF' s 10-Year PFCF Range
Min: 8.69   Max: 2760
Current: 17.7

8.69
2760
EV-to-EBIT 20.40
ALIOF's EV-to-EBIT is ranked higher than
50% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ALIOF: 20.40 )
ALIOF' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 272.5
Current: 20.4

7.9
272.5
PEG 3.80
ALIOF's PEG is ranked lower than
418% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ALIOF: 3.80 )
ALIOF' s 10-Year PEG Range
Min: 0   Max: 3.8
Current: 3.8

0
3.8
Shiller P/E 37.60
ALIOF's Shiller P/E is ranked lower than
327% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.60 vs. ALIOF: 37.60 )
ALIOF' s 10-Year Shiller P/E Range
Min: 0   Max: 37.6
Current: 37.6

0
37.6

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.70
ALIOF's Dividend Yield is ranked lower than
62% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. ALIOF: 0.70 )
ALIOF' s 10-Year Dividend Yield Range
Min: 0.99   Max: 1.45
Current: 0.7

0.99
1.45
Dividend Payout 0.16
ALIOF's Dividend Payout is ranked higher than
83% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. ALIOF: 0.16 )
ALIOF' s 10-Year Dividend Payout Range
Min: 0.48   Max: 0.74
Current: 0.16

0.48
0.74
Yield on cost (5-Year) 0.70
ALIOF's Yield on cost (5-Year) is ranked lower than
66% of the 169 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. ALIOF: 0.70 )
ALIOF' s 10-Year Yield on cost (5-Year) Range
Min: 0.99   Max: 1.45
Current: 0.7

0.99
1.45
Share Buyback Rate 1.70
ALIOF's Share Buyback Rate is ranked higher than
97% of the 696 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ALIOF: 1.70 )
ALIOF' s 10-Year Share Buyback Rate Range
Min: 1.7   Max: -81.7
Current: 1.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.80
ALIOF's Price/Tangible Book is ranked lower than
66% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ALIOF: 8.80 )
ALIOF' s 10-Year Price/Tangible Book Range
Min: 2.98   Max: 8.47
Current: 8.8

2.98
8.47
Price/DCF (Projected) 1.80
ALIOF's Price/DCF (Projected) is ranked lower than
279% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. ALIOF: 1.80 )
ALIOF' s 10-Year Price/DCF (Projected) Range
Min: 0   Max: 0
Current: 1.8

Price/Median PS Value 1.80
ALIOF's Price/Median PS Value is ranked higher than
54% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ALIOF: 1.80 )
ALIOF' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 4.85
Current: 1.8

0.62
4.85
Price/Graham Number 2.90
ALIOF's Price/Graham Number is ranked lower than
54% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. ALIOF: 2.90 )
ALIOF' s 10-Year Price/Graham Number Range
Min: 1.4   Max: 2.93
Current: 2.9

1.4
2.93
Earnings Yield (Greenblatt) 4.90
ALIOF's Earnings Yield (Greenblatt) is ranked higher than
60% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ALIOF: 4.90 )
ALIOF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 12.6
Current: 4.9

0.4
12.6

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:ATLNE.Switzerland, ATLN.Switzerland, ACT.Germany
Actelion Ltd, was founded in 1997 and is headquartered in Allschwil, Switzerland. The Company is a biopharmaceutical company, that engages in the discovery, development, and commercialization of low molecular weight drugs for unmet medical needs. Its products include Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; and Veletri, a formulation of epoprostenol for the treatment of PAH.
» More Articles for OTCPK:ALIOF

Headlines

Articles On GuruFocus.com
No related article found.

More From Our Partners
Good News for Cleveland BioLabs - Analyst Blog Apr 17 2014 - ZACKS

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide